http://www.diamyd.com/ Latest Press Releases and Financial Reports from Diamyd Medical. Copyright 2012. All rights reserved. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=655911 september 2011 - februari 2012 Delårsrapport Diamyd Medical AB (publ), räkenskapsåret 2011/2012 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) Perioden 1 december 2011 - 29 februari 2012 · Koncernens nettoomsättning uppgick till 0,6 (114,5) MSEK · Resultat efter finansnetto uppgick... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=655911 Wed, 04 Apr 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=655912 September 2011 - February 2012 Quarterly Report Diamyd Medical AB (publ), fiscal year 2011/2012 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) Reporting period December 1, 2011 - February 29, 2012 Group net sales amounted to MSEK 0.6 (114.5) Profit before tax amounted to MSEK -13.9... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=655912 Wed, 04 Apr 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=635760 En artikel med resultaten från Diamyd Medicals europeiska fas III-studie med den antigenbaserade diabetesterapin Diamyd® har publicerats i den vetenskapliga tidskriften the New England Journal of Medicine. De nu publicerade resultaten har tidigare presenterats på diabeteskonferensen "American... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=635760 Thu, 02 Feb 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=635761 An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England Journal of Medicine. The now published results were previously presented at the American Diabetes Association's 71st... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=635761 Thu, 02 Feb 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=633640 Delårsrapport Diamyd Medical AB (publ), räkenskapsåret 2011/2012 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=633640 Wed, 25 Jan 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=633641 Quarterly Report Diamyd Medical AB (publ), fiscal year 2011/2012 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=633641 Wed, 25 Jan 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=629530 Totalt 50 barn från fyra års ålder med hög risk att utveckla typ 1-diabetes har inkluderats i en forskarinitierad fas II-studie, DiAPREV-IT, med Diamyd Medicals diabetesvaccin Diamyd® och studien är därmed fullrekryterad. Syftet med studien är att utvärdera om förebyggande behandling med Diamyd® kan... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=629530 Mon, 09 Jan 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=629531 A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical's diabetes vaccine Diamyd®. The study is thus fully recruited. The purpose of the study is to evaluate whether... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=629531 Mon, 09 Jan 2012 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624548 Q1 . Results from Phase I study in cancer pain shows promising safety data and relief of chronic pain Q2 . Recruitment for US Phase III study in type 1 diabetes is completed . Phase II study in cancer pain is started . University of Florida Research Foundation initiates court case against Diamyd... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624548 Thu, 08 Dec 2011 18:42:23 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624230 Vid Diamyd Medicals ordinarie bolagsstämma den 7 december meddelade vd Peter Zerhouni att det gångna året har varit händelserikt och omskakande, men att bolaget nu står väl rustat att fortsätta utveckla innovativa läkemedel för sjukdomar som idag saknar effektiva behandlingsalternativ. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624230 Wed, 07 Dec 2011 19:18:12 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624231 At Diamyd Medical's Annual General Meeting on December 7, Peter Zerhouni, President and CEO, commented that the past year had been eventful and turbulent, but that the Company now stands well-equipped to continue its efforts to develop innovative pharmaceuticals for diseases for which there are... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=624231 Wed, 07 Dec 2011 19:18:12 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617953 University of Florida Research Foundation, Incorporated ("UFRF") och Diamyd Medical AB meddelar idag gemensamt att de nått en förlikning avseende den stämningsansökan som UFRF inkom med till United States Federal District Court i Florida, USA, mot Diamyd Medical i januari 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617953 Thu, 17 Nov 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617954 University of Florida Research Foundation, Incorporated ("UFRF"), and Diamyd Medical AB today jointly announced that they have settled the breach of contract litigation that UFRF filed in the United States Federal District Court in Florida against Diamyd Medical in January 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617954 Thu, 17 Nov 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617598 ÅRET I KORTHET Q1   . Resultat från fas I-studie i cancersmärta visar lovande säkerhetsdata och lindring avlångvarig smärta Q2   . Rekrytering fullbordas till amerikansk fas III-studie i typ 1-diabetes . Fas II-studie i cancersmärta startas . University of Florida Research Foundation inleder... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=617598 Wed, 16 Nov 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=615110 Följande kallelse till årsstämma kommer att hållas tillgänglig på Diamyd Medicals hemsida www.diamyd.com från och med onsdag den 9 november 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=615110 Mon, 07 Nov 2011 19:31:13 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=615111 The follwing summons to the Annual General Meeting will be available at Diamyd Medical's website www.diamyd.com from Wednesday November 9, 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=615111 Mon, 07 Nov 2011 19:31:13 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=608334 Bokslutskommuniké Stockholm 13 oktober 2011 1 september 2010 - 31 augusti 2011 Bokslutskommuniké Diamyd Medical AB (publ.), räkenskapsåret 2010/2011 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=608334 Thu, 13 Oct 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=608335 Year End Report, Stockholm, October 13, 2011 September 1, 2010 - August 31, 2011 Fourth quarter report for Diamyd Medical AB (publ.), fiscal year 2010/2011 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=608335 Thu, 13 Oct 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=599534 Diamyd Medical AB med samarbetspartners har fått ett forskningsanslag på tre miljoner dollar från amerikanska National Institutes of Health för att utveckla bolagets patenterade Nerve Targeting Drug Delivery System (NTDDS) för prevention av kemoterapi-inducerad perifer neuropati. Anslaget ger Diamyd... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=599534 Mon, 12 Sep 2011 08:30:00 +0100 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=599535 Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company's patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy. The grant allows Diamyd to expand the... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=599535 Mon, 12 Sep 2011 08:30:00 +0100